Baseline Cystatin C measurement is a potent predictor of adverse cardiovascular outcomes following ACS: A PROVE IT-TIMI 22 analysis

Authors

Gregory Giugliano MD, Baystate HealthFollow

Author Department

Medicine

Document Type

Presentations, Research

Publication Date

11-1-2006

Recommended Citation

American Heart Association Scientific Sessions. Abstract online at http://www.scienceondemand.org.